Genomes and Genes
Summary: An antilipemic agent and the biologically active metabolite of CLOFIBRATE.
Publications181 found, 100 shown here
- First-line therapies for lowering triglyceride levelsVasudevan A Raghavan
Am Fam Physician 77:416; author reply 417-8. 2008
- Effect of lipid-lowering drug therapy on small-dense low-density lipoproteinJames M Backes
Department of Pharmacy Practice, School of Pharmacy, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160 7231, USA
Ann Pharmacother 39:523-6. 2005..To review the effects of lipid-lowering therapy on small-dense low-density lipoprotein cholesterol (sdLDL-C)...
- Drugs and personal care products as ubiquitous pollutants: occurrence and distribution of clofibric acid, caffeine and DEET in the North SeaStefan Weigel
Institute of Organic Chemistry, University of Hamburg, Germany
Sci Total Environ 295:131-41. 2002..The method was applied to the screening of samples from different North Sea areas for clofibric acid, diclofenac, ibuprofen, ketoprofen, propyphenazone, caffeine and N,N-diethyl-3-toluamide (DEET)...
- Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trialsRakesh S Birjmohun
Department of Vascular Medicine, Academic Medical Center of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
J Am Coll Cardiol 45:185-97. 2005..The aim of this research was to estimate the efficacy and safety of current high-density lipoprotein cholesterol (HDL-C)-increasing drugs...
- Liver gene expression profiles of rats treated with clofibric acid: comparison of whole liver and laser capture microdissected liverCecile Michel
Department of Drug Safety Evaluation, Aventis Pharma, Vitry sur Seine, France
Am J Pathol 163:2191-9. 2003b>Clofibric acid (CLO) is a peroxisome proliferator (PP) that acts through the peroxisome proliferator activated receptor alpha, leading to hepatocarcinogenesis in rodents...
- Effects of clofibric acid on mRNA expression profiles in primary cultures of rat, mouse and human hepatocytesLysiane Richert
Laboratoire de Biologie Cellulaire, UFR SMP, 4, Place Saint Jacques, 25030 Besancon, France
Toxicol Appl Pharmacol 191:130-46. 2003The mRNA expression profile in control and clofibric acid (CLO)-treated mouse, rat, and human hepatocytes was analyzed using species-specific oligonucleotide DNA microarrays (Affymetrix)...
- Properties of Ca(2+) release induced by clofibric acid from the sarcoplasmic reticulum of mouse skeletal muscle fibresT Ikemoto
Department of Pharmacology, Saitama Medical School, Moroyama machi, Saitama 350 0495, Japan
Br J Pharmacol 134:719-28. 20011. To characterize the effect of clofibric acid (Clof) on the Ca(2+) release mechanism in the sarcoplasmic reticulum (SR) of skeletal muscle, we analysed the properties of Clof-induced Ca(2+) release under various conditions using ..
- Liver gene expression in rats in response to the peroxisome proliferator-activated receptor-alpha agonist ciprofibrateFekadu Yadetie
Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, N 7489 Trondheim, Norway
Physiol Genomics 15:9-19. 2003....
- Differential induction of peroxisomal beta-oxidation enzymes by clofibric acid and aspirin in piglet tissuesX X Yu
Division of Nutritional Sciences, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, USA
Am J Physiol Regul Integr Comp Physiol 281:R1553-61. 2001..5% clofibric acid (CA) or 1% aspirin for 14 days. CA increased ratios of liver weight to body weight (P < 0...
- Comparison of the acute and chronic mitogenic effects of the peroxisome proliferators methylclofenapate and clofibric acid in rat liverN C Barrass
Zeneca Pharmaceuticals, Macclesfield, Cheshire, UK
Carcinogenesis 14:1451-6. 1993..of acute (1 week) and chronic (26 week) exposure to the peroxisome proliferators methylclofenapate (MCP) and clofibric acid (CA), at 0.05 and 0.5% in the diet respectively, on hepatocyte replication in the Sprague-Dawley rat...
- Combined treatment with fibrates and small doses of atorvastatin in patients with mixed hyperlipidemiaGeorge Liamis
Department of Internal Medicine, University of Ioannina, Greece
Curr Med Res Opin 18:125-8. 2002..We conclude that the careful administration of small doses of atorvastatin in patients with mixed dyslipidemia receiving fibrates is associated with a significant amelioration of lipid abnormalities...
- Hepatic beta-oxidation and carnitine palmitoyltransferase I in neonatal pigs after dietary treatments of clofibric acid, isoproterenol, and medium-chain triglyceridesPasha Lyvers Peffer
Department of Animal Science, North Carolina State University, Raleigh, NC, USA
Am J Physiol Regul Integr Comp Physiol 288:R1518-24. 2005..The long-chain control diet was supplemented further with clofibric acid (0.5%) or isoproterenol (40 ppm), and growth was monitored for 10-12 days...
- Clofibric acid, a peroxisome proliferator-activated receptor alpha ligand, inhibits growth of human ovarian cancerYoshihito Yokoyama
Department of Obstetrics and Gynecology, Hirosaki University School of Medicine, Hirosaki, Amori, Japan
Mol Cancer Ther 6:1379-86. 2007..In this study, we investigated the inhibitory effect of clofibric acid (CA), a ligand for PPARalpha on growth of ovarian malignancy, in in vivo and in vitro experiments using OVCAR-..
- Effect of different antilipidemic agents and diets on mortality: a systematic reviewMarco Studer
Basel Institute for Clinical Epidemiology, University Hospital Basel, CH-4031 Basel, Switzerland
Arch Intern Med 165:725-30. 2005..Any potential reduction in cardiac mortality from fibrates is offset by an increased risk of death from noncardiovascular causes...
- Pharmacological characterization of chloride channels belonging to the ClC family by the use of chiral clofibric acid derivativesM Pusch
Istituto di Cibernetica e Biofisica, CNR, Genova, Universita di Bari, Bari, Italy
Mol Pharmacol 58:498-507. 2000..No effects were observed on ClC-5 that shows less than 30% homology with ClC-1. Thus, CPP-like compounds may be useful both to gain insight into biophysical properties of ClC-1 and for searching tissue-specific therapeutic agents...
- Fibric acid derivatives in cardiovascular disease prevention: results from the large clinical trialsSander J Robins
Boston University School of Medicine, Massachussetts, USA
Curr Opin Lipidol 17:431-9. 2006..This review focuses on a number of extended analyses from these trials that may relate to the success or failure of fibrate therapy and indicate who might likely benefit from this therapy...
- Determination of rice herbicides, their transformation products and clofibric acid using on-line solid-phase extraction followed by liquid chromatography with diode array and atmospheric pressure chemical ionization mass spectrometric detectionT C Santos
Department of Chemistry, , , Brazil
J Chromatogr A 879:3-12. 2000..During the 3-month monitoring of the herbicides, 8-hydroxybentazone and 4-chloro-2-methylphenoxyacetic acid were successively found in those samples...
- Therapeutic roles of peroxisome proliferator-activated receptor agonistsBart Staels
Department of Atherosclerosis, Unité INSERM 545 Institut Pasteur, 1, rue du Professeur Calmette, 59019 Lille Cedex, France
Diabetes 54:2460-70. 2005..The functions of a third PPAR isoform, PPARdelta, and its potential as a therapeutic target are currently under investigation...
- Hepatocellular DNA synthesis in rats given peroxisome proliferating agents: comparison of WY-14,643 to clofibric acid, nafenopin and LY171883P I Eacho
Toxicology Division, Eli Lilly Company, Greenfield, IN 46140
Carcinogenesis 12:1557-61. 1991..In these studies, WY-14,643 was compared to clofibric acid, nafenopin and LY171883 given to rats in the diet for up to 30 days...
- Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugsDavid J Graham
Office of of Drug Safety, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD 20857, USA
JAMA 292:2585-90. 2004..Lipid-lowering agents are widely prescribed in the United States. Reliable estimates of rhabdomyolysis risk with various lipid-lowering agents are not available...
- Clinical practice. HypertriglyceridemiaJohn D Brunzell
Department of Medicine, Division of Metabolism, Endocrinology, and Nutrition, and the Northwest Lipid Metabolism and Diabetes Research Laboratories, University of Washington, Seattle, USA
N Engl J Med 357:1009-17. 2007
- The role of fibric acids in atherosclerosisJ C Fruchart
, , 2 Inserm U325, Lille, France
Curr Atheroscler Rep 3:83-92. 2001..Further clinical studies are necessary to investigate if fibric acids decrease cardiovascular mortality in type 2 diabetes and in primary prevention of hypertriglyceridemia and hypolipidemia...
- Role for fibrate therapy in diabetes: evidence before FIELDBruno Verges
Service Endocrinologie, diabétologie et maladies métaboliques, Centre Hospitalier, Universitaire de Dijon, and INSERM U498, Faculte de Medecine, Dijon, France
Curr Opin Lipidol 16:648-51. 2005..Statins have been shown to diminish significantly the risk for coronary disease in patients with type 2 diabetes, and so what are the real effects of fibrates on cardiovascular risk in type 2 diabetes?..
- Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9Sanae Kourimate
INSERM U915, CHU Hotel Dieu, 9 quai Moncousu, Nantes, France
J Biol Chem 283:9666-73. 2008..Moreover, this study validates the functional relevance of a combined therapy associating PCSK9 repressors and statins...
- Clofibric acid stimulates branched-chain amino acid catabolism by three mechanismsRumi Kobayashi
Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN 46202-5122, USA
Arch Biochem Biophys 407:231-40. 2002..WY-14,643, which, like clofibric acid, is a ligand for the peroxisome-proliferator-activated receptor alpha [PPARalpha], does not directly inhibit ..
- Role of fibric acid derivatives in the management of risk factors for coronary heart diseaseJean Pierre Despres
Quebec Heart Institute, Laval Hospital Research Center, Quebec, Canada
Drugs 64:2177-98. 2004....
- Cardiovascular disease with diabetes or the metabolic syndrome: should statins or fibrates be first line lipid therapy?Sander J Robins
Division of Endocrinology, Nutrition, and Diabetes, Boston University School of Medicine, Evans 201, 88 East Newton Street, Boston, MA 02118, USA
Curr Opin Lipidol 14:575-83. 2003....
- Octreotide inhibits the enterochromaffin-like cell but not peroxisome proliferator-induced hypergastrinemiaI Bakke
Department of Physiology and Biomedical Engineering, Norwegian University of Science and Technology, Trondheim, Norway
J Mol Endocrinol 25:109-19. 2000..Ciprofibrate stimulates gastrin cell activity by a mechanism unaffected by octreotide, but octreotide does inhibit basal and gastrin-stimulated ECL cell function and growth...
- Effects of the peroxisome proliferator clofibric acid on superoxide dismutase expression in the human HepG2 hepatoma cell lineP Becuwe
Laboratoire de Biologie Cellulaire du Developpement, Upres 2402 Proliferateurs de Peroxysomes, Universite Henri Poincare Nancy I, Faculte des Sciences, Vandoeuvre les Nancy, France
Biochem Pharmacol 58:1025-33. 1999We examined the effects of clofibric acid, a peroxisome proliferator, on the production of superoxide radicals, on the levels of malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE), and on the expression of superoxide dismutases (SODs) in ..
- [Low HDL-cholesterol, high triglycerides--well known but often ignored]R Benz
Medizinische Poliklinik, Hypertonie und Adipositassprechstunde, Universitatsspital Zurich
Praxis (Bern 1994) 93:1911-6. 2004..We therefore want to show the relation of the triglyzerides with the HDL-Cholesterol and the nonpharmacologic treatment of these two factors. Some clinical examples are illustrating the topic...
- Treatment of dyslipidemia to reduce cardiovascular risk in patients with multiple risk factorsChristie M Ballantyne
Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
Clin Cornerstone 8:S6-13. 2007..Weight loss has also been shown to improve risk factors associated with metabolic syndrome...
- [When should an association of lipid-lowering drugs be proposed in a patient failing to reach therapeutic targets under monotherapy? Guidelines of the New French Society of Atherosclerosis]M Farnier
Point Medical, Rond Point de la Nation, 21000 Dijon
Arch Mal Coeur Vaiss 100:569-81. 2007
- Treating hypertriglyceridemiaBruce J Holub
CMAJ 177:604; author reply 604-5. 2007
- Utility of currently available modes of therapy in reaching lipid goalsKelly Anne Spratt
University of Pennsylvania Health System, Cardiovascular Division, Philadelphia Heart Institute, Second Floor, 39th and Market Streets, Philadelphia, PA 19104, USA
J Am Osteopath Assoc 104:S14-6. 2004..In addition, nonprescription agents such as plant stanols and sterols are available to modify plasma lipid levels. These agents can be used individually or coadministered to achieve lipid goals...
- Management of dyslipidemia in women in the post-hormone therapy eraLori Mosca
Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA
J Gen Intern Med 20:297-305. 2005..This article reviews these recommendations and the evidence supporting them...
- Is it time to stop treating dyslipidaemia with fibrates?Jocelyne R Benatar
Cardiovascular Research Unit, Green Lane Clinical Centre, Green Lane, Auckland
N Z Med J 120:U2706. 2007..To determine whether evidence from randomised clinical trials supports the use of fibrates to reduce non-fatal and fatal cardiovascular events in patients with dyslipidaemia...
- Rationale for combination therapy with statin drugs in the treatment of dyslipidemiaBenjamin J Ansell
Division of General Internal Medicine Cardiology, David Geffen UCLA School of Medicine, Los Angeles, CA 90095, USA
Curr Atheroscler Rep 7:29-33. 2005..More recently, however, it has been recognized that the potential complications of this combination are far outweighed by the clinical benefits that are possible...
- Hypertriglyceridemia: its etiology, effects and treatmentGeorge Yuan
Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ont
CMAJ 176:1113-20. 2007..We review the causes and classification of elevated triglyceride levels, the clinical manifestations of primary hypertriglyceridemia and the management of patients with elevated triglyceride levels...
- Management of diabetic dyslipidemia: need for reappraisal of the goalsAmit Khera
Division of Cardiology and the Donald W. Reynolds Cardiovascular Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9047, USA
Am J Cardiovasc Drugs 5:83-91. 2005..Several ongoing trials of various pharmacologic agents should help clarify the role of these agents alone and in combination with HMG-CoA reductase inhibitors in the management of diabetic dyslipidemia...
- Coadministration of multidrug therapy to achieve lipid goalsMargo A Denke
The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr, San Antonio, TX 78284, USA
J Am Osteopath Assoc 104:S17-22. 2004..The coadministration of low doses of these agents has been proved to be as effective as high-dose statin therapy in reducing LDL-C levels and assisting patients achieve their treatment goals...
- Treating hypertriglyceridemiaGeorg Roggla
CMAJ 177:603; author reply 604-5. 2007
- Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolismJean Charles Fruchart
Lipoprotein and Atherosclerosis Research Unit, INSERM Unité de Recherche sur l Arthérosclérose and Lille University 2 U545, Pasteur Institute of Lille, Lille, France
Drugs Today (Barc) 42:39-64. 2006..PPARs are also expressed in atherosclerotic lesions...
- Management of hypertriglyceridemiaRobert C Oh
Family Medicine Residency Program, Tripler Army Medical Center, Honolulu, Hawaii 96859, USA
Am Fam Physician 75:1365-71. 2007..e., 500 mg per dL [5.65 mmol per L] or higher) is aimed at reducing the risk of acute pancreatitis. Statins, fibrates, niacin, and fish oil (alone or in various combinations) are effective when pharmacotherapy is indicated...
- [Metabolically designed treatments: from biochemistry to the vessel lining]P Moulin
, , 69677 Bron, France
Rev Med Interne 28:S12-3. 2007
- Is there evidence for the evidence-based guidelines for cardiovascular disease prevention in women?Barbara H Roberts
The Women s Cardiac Center at The Miriam Hospital, Providence, RI 02906, USA
Gend Med 3:5-12. 2006
- [Treatment of dyslipidemia: how and when to combine lipid lowering drugs]Isio Schulz
Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP
Arq Bras Endocrinol Metabol 50:344-59. 2006..Niacin causes flushing, that can in part be managed with use of aspirin and extended release forms (Niaspan); niacin also may increase plasma glucose and uric acid levels. Evaluation of risks and benefits for each patient is needed...
- Dyslipidaemia, hypercoagulability and the metabolic syndromeAnna I Kakafika
Department of Clinical Biochemistry, Royal Free Hospital, Royal Free and University College Medical School, London, UK
Curr Vasc Pharmacol 4:175-83. 2006..Obesity and sedentary lifestyle coupled with genetic factors interact to produce the syndrome. Here, we consider two components of the metabolic syndrome, dyslipidaemia and hypercoagulability...
- [Nuclear receptors PPARalpha]V Soska
Centrum pro diagnostiku a lécbu dyslipidemií Oddelení klinického komplementu FN u sv Anny, Brno
Vnitr Lek 52:628-31. 2006..These effects are very important in patients with metabolic syndrom...
- [Clinical trials of statins and fibrates --a meta-analysis]Vid Stanulović
Accelsiors CRO and Consultancy Services, Budapest, Hungary
Med Pregl 59:213-8. 2006..The question remains: which trial should be the basis of clinical decision making in the choice of hypolipidemic therapy?..
- [Favorable effects of decreasing lipids in patients with diabetes mellitus]I Gouni-Berthold
Klinik II und Poliklinik für Innere Medizin der Universität zu Köln, Koln, Germany
Dtsch Med Wochenschr 131:S252-4. 2006..Therefore, at present no specific recommendation for treatment of diabetics with fibrates can be made...
- Fibrates after the FIELD study: Some answers, more questionsAnthony S Wierzbicki
St Thomas Hospital, London, SE1 7EH, UK
Diab Vasc Dis Res 3:166-71. 2006....
- [New indications and therapeutic objectives for dyslipidemia]Antonio Maiques Galán
Aten Primaria 38:473-5. 2006
- Fibrates: what have we learned in the past 40 years?James M Backes
Department of Pharmacy Practice, University of Kansas School of Pharmacy, Lawrence, Kansas, USA
Pharmacotherapy 27:412-24. 2007..Nearly 40 years after the introduction of the fibrates, practitioners are still contemplating the role of these agents in the treatment of CHD...
- [Continuing care of patients with cardiovascular risk in general practice: patients with dyslipidemia and their care]Zoltán Jancsó
Debreceni Egyetem, Orvos és Egészségtudományi Centrum, Általános Orvostudományi Kar, Családorvosi Tanszék
Orv Hetil 146:2629-33. 2005..The role of dyslipidemia is essential in the development of atherosclerosis, therefore continuing care of dyslipidemic patients is an extremely important task in cardiovascular prevention...
- Hypertriglyceridemia and cardiovascular risk reductionTerry A Jacobson
Office of Health Promotion and Disease Prevention, Emory University, Atlanta, GA 30303, USA
Clin Ther 29:763-77. 2007..There is evidence that elevated TG levels may be a significant independent risk factor for coronary heart disease (CHD), particularly in women...
- Treating hypertriglyceridemiaIrfan Yavasoglu
CMAJ 177:603-4; author reply 604-5. 2007
- Beyond the statins: new therapeutic perspectives in cardiovascular disease preventionM John Chapman
Institut National de la Santé et de la Recherche Mé dicale, Hopital de la Pitie, Paris, France
Cardiovasc Drugs Ther 19:135-9. 2005..Given that the prevalence of low HDL-C, particularly amongst individuals with CHD, is higher than previously anticipated, combining nicotinic acid and a statin represents an innovative approach to further reducing CHD risk...
- Monocyte release of tumor necrosis factor-alpha and interleukin-1beta in primary type IIa and IIb dyslipidemic patients treated with statins or fibratesBogusław Okopień
Department of Clinical Pharmacology, Medical University of Silesia, Medykow 18, PL 40 752 Katowice, Poland
J Cardiovasc Pharmacol 46:377-86. 2005..The statin- and fibrate-induced suppression of proinflammatory cytokine release from monocytes seems to play a role in their beneficial effect on the incidence of cardiovascular events...
- Patients with low levels of high-density lipoprotein cholesterol: to treat or not to treat?S Tavintharan
Department of Medicine, Alexandra Hospital, 378 Alexandra Road, Singapore 159964
Singapore Med J 46:519-28. 2005..CETP inhibitors show greater HDL-C rising, but are still used in trial settings only. HDL mimetic agents are another group of agents that offer much promise. Clinical outcome data are awaited for these newer therapeutic agents...
- Lipids in type 2 diabetesMarkku Laakso
Department of Medicine, University of Kuopio, Kuopio, Finland
Semin Vasc Med 2:59-66. 2002....
- Differential associations of statin and fibrate treatment with carotid arterial remodelingGilles Chironi
, , Paris, France
Am J Hypertens 18:1476-81. 2005..These differences were not explained by differences in LDL cholesterol...
- Modifying plasma low-density lipoprotein and high-density lipoprotein cholesterol: what combinations are available in the future?John J P Kastelein
Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Am J Cardiol 96:20K-27K; discussion 34K-35K. 2005..Management of the metabolic syndrome focusing on the modification of plasma LDL as well as high-density lipoprotein cholesterol is reviewed. Future management strategies with the use of novel combination therapy is also discussed...
- Strategies for management and treatment of dyslipidemia in HIV/AIDSP E Sax
Division of Infection, Diseases and HIV Program, Brigham and Women s Hospital, Boston, MA 02115, USA
AIDS Care 18:149-57. 2006..Each approach is associated with advantages and limitations and the need to maintain viral suppression must be balanced with the need to treat abnormal lipid levels...
- Assessment of compliance with lipid guidelines in an academic medical centerSarah J Schwiesow
Kaiser Permanente, Highlands Ranch, CO 80129 2262, USA
Ann Pharmacother 40:27-31. 2006..Emerging evidence supports the recognition and management of secondary lipid goals, high-density lipoprotein cholesterol (HDL-C) level greater than 40 mg/dL, and triglyceride level less than 150 mg/dL...
- Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactionsMichael H Davidson
Rush University, Preventive Cardiology Center, Rush Presbyterian St Luke s Medical Center, 515 State Street, Suite 2700, Chicago, IL, USA
Expert Opin Drug Saf 5:145-56. 2006..The Action to Control Cardiovascular Risk in Diabetes (ACCORD) study in 10,000 patients with Type 2 diabetes mellitus is testing the efficacy and safety of fenofibrate/statin combination...
- Low-density lipoprotein size and cardiovascular risk assessmentM Rizzo
Department of Clinical Medicine and Emerging Diseases, University of Palermo, Italy
QJM 99:1-14. 2006....
- Management of hyperlipidemia: new LDL-C targets for persons at high-risk for cardiovascular eventsEbrahim A Balbisi
Department of Clinical Pharmacy Practice, College of Pharmacy and Allied Health Professions, St John s University, New York, NY, USA
Med Sci Monit 12:RA34-9. 2006..In spite of the challenges, there are ample opportunities for improving the management of hyperlipidemia. Adherence to the recommendations will vastly reduce morbidity and mortality associated with CHD...
- Expert commentary: the safety of fibrates in lipid-lowering therapyW Virgil Brown
Emory University School of Medicine, Atlanta, Georgia, USA
Am J Cardiol 99:19C-21C. 2007..To date, there has been no study exclusive to patients with elevated triglycerides, raising the question of the potential benefit of these drugs in patients with the lipid abnormalities most effectively treated with fibrates...
- [Adverse effects of lipid-lowering medications]Yoshihiro Fukumoto
Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine
Nippon Rinsho 65:165-72. 2007
- Treatment of dyslipoproteinemia in the metabolic syndromeA Steinmetz
St. Nikolaus-Stiftshospital, Teaching Hospital, University of Bonn at Andernach, Germany
Exp Clin Endocrinol Diabetes 109:S548-59. 2001..However studies still are needed showing definite evidence on differential therapy in lipid lowering based on prospective controlled trials with endpoints of macro- and microangiopathy in diabetic patients...
- Hypertriglyceridemia and cardiovascular disease managementRonald A Codario
J Am Acad Nurse Pract 19:7-10, 13-4. 2007
- High-density lipoprotein metabolism: potential therapeutic targetsMichael H Davidson
University of Chicago, Pritzker School of Medicine, Chicago, Illinois, USA
Am J Cardiol 100:n32-40. 2007....
- Atorvastatin versus four statin-fibrate combinations in patients with familial combined hyperlipidaemiaVasilios G Athyros
Lipid Out patient Clinic, Division of Cardiology, 2nd Propedeutic Department of Internal Medicine, Aristotelian University, Hippocration Hospital, 49 Konstantinoupoleos St, Thessaloniki, 546 42, Greece
J Cardiovasc Risk 9:33-9. 2002..Nonetheless, they have not been extensively used because of the fear of side effects. Thus, a therapeutic alternative is required for this lipid disorder...
- Current drug treatments for lipid managementNeil J Stone
Feinberg School of Medicine, Northwestern University, Chicago, USA
Manag Care 11:4-9. 2002
- Management of hyperlipidemia with statins in the older patientWilbert S Aronow
Department of Medicine, Cardiology and Geriatrics Divisions, New York Medical College, Valhalla, NY 10595, USA
Clin Interv Aging 1:433-8. 2006..When LDL cholesterol-lowering drug therapy is used to treat high-risk persons or moderately high-risk persons, the serum LDL cholesterol should be decreased at least 30% to 40%...
- Targeting high-density lipoprotein cholesterol in the management of cardiovascular diseaseMichael H Davidson
Pritzker School of Medicine, University of Chicago, Chicago, IL, USA
Am Heart Hosp J 5:210-6. 2007..This article reviews the strategies for targeting HDL cholesterol to optimize outcomes in CHD...
- [Therapy of dyslipidemia in post-infarction: state of the art]M C Borgia
Dipartimento di Scienze Cliniche, Universita Sapienza, Roma, Italia
Clin Ter 158:523-32. 2007..The innovative therapeutic approach to hypercholesterolemia today is based on a double inhibition of cholesterol synthesis and absorption combining a statin with ezetimibe...
- Does the addition of fibrates to statin therapy have a favorable risk to benefit ratio?Eliot A Brinton
Cardiovascular Genetics, University of Utah School of Medicine, 420 Chipeta Way, Room 1160, Salt Lake City, UT 84108, USA
Curr Atheroscler Rep 10:25-32. 2008..This review provides an update on the benefits and risks of fibrate monotherapy and addresses the benefits and risks of adding fibrates to statins...
- [Long-term hypolipidemic treatment of mixed hyperlipidemia with a combination of statins and fibrates]M Zeman
IV interni klinika 1 LF UK a VFN, Praha
Cas Lek Cesk 142:500-4. 2003..Aim of the study was to evaluate efficacy and safety of long-term treatment of pravastatin + fenofibrate or simvastatin + ciprofibrate therapy in the high-risk group of patients with severe mixed hyperlipoproteinemia...
- Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomesMadiha Abdel-Maksoud
Department of Public Health, Preventive, and Social Medicine, Tanta University, Egypt
J Cardiovasc Pharmacol 51:331-51. 2008....
- Managing dyslipidemia in chronic kidney diseaseCharles R Harper
Department of Medicine, Emory University, Atlanta, Georgia 30303, USA
J Am Coll Cardiol 51:2375-84. 2008..After reviewing the safety and dose alterations required in managing dyslipidemia in patients with CKD, a practical treatment algorithm is proposed...
- Fibrates and future PPARalpha agonists in the treatment of cardiovascular diseaseBart Staels
Department of Atherosclerosis, Institut Pasteur de Lille, UMR545 Inserm, University of Lille 2, Lille, France
Nat Clin Pract Cardiovasc Med 5:542-53. 2008....
- The treatment of dyslipidemia--what's left in the pipeline?Oliver Rau
Institute of Pharmaceutcial Chemistry ZAFES, Johann Wolfgang Goethe University Frankfurt, Max von Laue Strasse 9, 60438 Frankfurt, Germany
ChemMedChem 3:206-21. 2008..Clinical implications of new drugs under investigation are discussed in this review...
- Lipid levels and cardiovascular risk in elderly women: a general population study of the effects of hormonal treatment and lipid-lowering agentsA M Dupuy
INSERM U888, Montpellier, France
Climacteric 11:74-83. 2008..To evaluate plasma lipid levels in elderly women in the general population as a function of use of lipid-lowering agents (LLA) and hormone therapy (HT)...
- Role of hepatic fatty acid:coenzyme A ligases in the metabolism of xenobiotic carboxylic acidsK M Knights
Department of Clinical Pharmacology, School of Medicine, Faculty of Health Sciences, Flinders University of South Australia, Australia
Clin Exp Pharmacol Physiol 25:776-82. 1998..g. clofibric acid) and of the R(-)-enantiomers of the commonly used 2-arylpropionic acid non-steroidal anti-inflammatory drugs (..
- Expression of rabbit cytochromes P4504A which catalyze the omega-hydroxylation of arachidonic acid, fatty acids, and prostaglandinsL J Roman
Department of Biochemistry, University of Texas Health Science Center at San Antonio 78284 7760
Arch Biochem Biophys 307:57-65. 1993..is the most abundant of the mRNAs, but it was not induced in kidney and only moderately (2-fold) in liver by clofibric acid. CYP4A7 exhibits a similar pattern of induction by clofibrate...
- The role of phosphatidylethanolamine methylation in the secretion of very low density lipoproteins by cultured rat hepatocytes: rapid inhibition of phosphatidylethanolamine methylation by bezafibrate increases the density of apolipoprotein B48-containing T Nishimaki-Mogami
National Institute of Health Sciences, Tokyo, Japan
Biochim Biophys Acta 1304:21-31. 1996..We have shown that bezafibrate and clofibric acid, known hypolipidemic agents, are potent inhibitors of PE methylation (see accompanying paper by Nishimaki-..
- Ecotoxicity assessment of lipid regulators in water and biologically treated wastewater using three aquatic organismsRoberto Rosal
Departamento de Ingenieria Quimica, Universidad de Alcala, 28871 Alcala de Henares, Madrid, Spain
Environ Sci Pollut Res Int 17:135-44. 2010..This paper describes a study undertaken to evaluate the acute toxicity of bezafibrate, clofibric acid, gemfibrozil, and fenofibric acid, a metabolite of fenofibrate whose ecotoxicity has not been previously ..
- Pharmaceutical and personal care products in sewage treatment worksRakesh Kanda
WRc NSF Limited, Henley Road, Medmenham, Marlow, Buckinghamshire, UK SL7 2HD
J Environ Monit 5:823-30. 2003..this study a number of PPCPs including painkillers (aspirin, ibuprofen), cholesterol control medication (clofibric acid), antibacterial agents (triclosan), musks (including galaxolide and tonalide), X-ray contrast media (..
- Distribution of acidic and neutral drugs in surface waters near sewage treatment plants in the lower Great Lakes, CanadaChris D Metcalfe
Water Quality Centre, Trent University, Peterborough, Ontario K9J 7B8, Canada
Environ Toxicol Chem 22:2881-9. 2003..However, clofibric acid, ketoprofen, fenoprofen, and carbamazepine were detected in samples collected in the summer of 2000 at sites ..
- Induction of acyl-CoA oxidase and cytochrome P450IVA1 RNA in rat primary hepatocyte culture by peroxisome proliferatorsD R Bell
Biochemical Toxicology, ICI Central Toxicology Laboratory, Macclesfield, Cheshire, U K
Biochem J 280:249-53. 1991..Hepatocytes were cultured with a maximal inducing dose of the peroxisome proliferator clofibric acid (1 mM), or vehicle control, for 4 days, and the level of RNAs compared with the level in rats which had been ..
- Bioactivation of carboxylic acid compounds by UDP-Glucuronosyltransferases to DNA-damaging intermediates: role of glycoxidation and oxidative stress in genotoxicityBenedetta C Sallustio
Department of Cardiology and Clinical Pharmacology, The Queen Elizabeth Hospital, Woodville 5011, Australia
Chem Res Toxicol 19:683-91. 2006..We have previously reported that clofibric acid undergoes glucuronidation-dependent bioactivation to DNA-damaging species in cultured mouse hepatocytes...
- Human pharmaceuticals, antioxidants, and plasticizers in wastewater treatment plant and water reclamation plant effluentsMary A Soliman
Department of Environmental Health Sciences, University of California, Los Angeles, USA
Water Environ Res 79:156-67. 2007..Carbamazepine, clofibric acid, gemfibrozil, ibuprofen, p-toluenesulfonamide, caffeine, butylated hydroxyanisole (BHA), butylated ..
- Purification, characterization, regulation and molecular cloning of mitochondrial protein kinasesR A Harris
Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis 46202
Adv Enzyme Regul 32:267-84. 1992..evidence was found for induction of the branched-chain alpha-ketoacid dehydrogenase complex nor its kinase by clofibric acid. Rather, clofibric acid is a potent inhibitor of the activity of the branched-chain alpha-ketoacid ..
- Effect of cryopreservation on cytochrome P-450 enzyme induction in cultured rat hepatocytesA Madan
XenoTech, Limited Liability Company, Kansas City, Kansas 66103, USA
Drug Metab Dispos 27:327-35. 1999..P-450 (CYP) CYP1A, CYP2B, CYP3A, and CYP4A by beta-naphthoflavone, phenobarbital, dexamethasone, and clofibric acid, respectively, in primary hepatocyte cultures prepared from both fresh and cryopreserved rat hepatocytes...
- Inhibition of rat peroxisomal palmitoyl-CoA ligase by xenobiotic carboxylic acidsB J Roberts
Department of Clinical Pharmacology, Flinders University of South Australia, Adelaide
Biochem Pharmacol 44:261-7. 1992..Valproic acid, clofibric acid, salicylic acid and 2,4-dichlorophenoxy-acetate were non-inhibitory at all concentrations studied (0.1-2.5 mM)...
- Effect of some peroxisome proliferators on transforming growth factor-beta 1 gene expression and insulin-like growth factor II/mannose-6-phosphate receptor gene expression in rat liverP C Rumsby
BIBRA Toxicology International, Carshalton, Surrey, UK
Carcinogenesis 15:419-21. 1994..control), 80 mg/kg nafenopin (NAF), 50 mg/kg methylclofenapate (MCP), 50 mg/kg Wy-14,643 (WY) or 250 mg/kg clofibric acid (CA) for 7 days...
- Occurrence and risk assessment of acidic pharmaceuticals in the Yellow River, Hai River and Liao River of north ChinaLi Wang
State Key Laboratory of Organic Geochemistry, Guangzhou Institute of Geochemistry, Chinese Academy of Sciences, Guangzhou 510640, China
Sci Total Environ 408:3139-47. 2010..We investigated the occurrence of twelve acidic pharmaceuticals and herbicides (salicylic acid, clofibric acid, ibuprofen, gemfibrozil, fenoprofen, naproxen, ketoprofen, mefenamic acid, tolfenamic acid, diclofenac, ..
- Characteristics of dehydroepiandrosterone as a peroxisome proliferatorJ Yamada
Department of Clinical Biochemistry, Tokyo College of Pharmacy, Japan
Biochim Biophys Acta 1092:233-43. 1991..in enzyme induction caused by dehydroepiandrosterone correlate well with those observed in the treatment of clofibric acid, a peroxisome proliferator...
- Clofibrate treatment promotes branched-chain amino acid catabolism and decreases the phosphorylation state of mTOR, eIF4E-BP1, and S6K1 in rat liverHiroki Ishiguro
Department of Gastroenterology, Nagoya University School of Medicine, Nagoya 466 8550, Japan
Life Sci 79:737-43. 2006..b>Clofibric acid (an active metabolite of clofibrate) is known to promote the BCAA catabolism by activation of branched-chain ..
- Influence of pharmaceutical residues on the structure of activated sludge bacterial communities in wastewater treatment bioreactorsBarbara Kraigher
Chair of Microbiology, Department of Food Science and Technology, Biotechnical Faculty, University of Ljubljana, Ljubljana, Slovenia
Water Res 42:4578-88. 2008..and 500microgL(-1)) of several commonly used pharmaceuticals (ibuprofen, naproxen, ketoprofen, diclofenac and clofibric acid)...
- CLINICAL STUDIES IN NUTRITION AND METABOLISMIshwarlal Jialal; Fiscal Year: 2007....
- DIETS FOR DYSLIPIDEMIA IN THE METABOLIC SYNDROMERobert Knopp; Fiscal Year: 2007..This study will be the first to demonstrate dietary benefit for dyslipidemia, inflammation and vascular stress in MetS at stable weight. ..
- POSTDOCTORAL TRAINING IN ARTERIOSCLEROSIS RESEARCHHenry Ginsberg; Fiscal Year: 2007..D. and Ph.D. faculty, other M.D. and Ph.D. postdoctoral scientists, and graduate students. A pro-active program to enhance recruitment of scientists from underrepresented ethnic groups is proposed. ..
- Obesity, Inflammation and Thrombosis: LOOK AHEADChristie Ballantyne; Fiscal Year: 2007....
- C-Reactive Protein And AtherosclerosisIshwarlal Jialal; Fiscal Year: 2007..Thus, these studies will clearly provide us with further scientific evidence in support of the role of CRP in atherothrombosis. ..
- Clinical and Translational Science AwardHenry Ginsberg; Fiscal Year: 2007..Pediatfic and community-based G/T research will receive special attention. The IICTR and CTSA will break down the barriers impeding movement of new knowledge from the bench to the bedside and community. ..
- Family Cardiac Caregiver Investigation to Evaluate Outcomes (FIT-O)Lori J Mosca; Fiscal Year: 2010..Improved adherence to evidence-based preventive therapies could have a substantial public health benefit. ..
- Role of PPARalpha and L-FABP in Acute Renal FailureDidier Portilla; Fiscal Year: 2010....
- T Cells, Macrophages, Chemokines, and Adiposopathy in Diet-Induced ObesityChristie M Ballantyne; Fiscal Year: 2010..To test our hypothesis, we will study the effects of diet-induced obesity on a number of factors related to inflammation in mice and also in human fat cells. ..
- DIETS FOR DYSLIPIDEMIA IN THE METABOLIC SYNDROMERobert Knopp; Fiscal Year: 2009..This study will be the first to demonstrate dietary benefit for dyslipidemia, inflammation and vascular stress in MetS at stable weight. ..
- CRP, Diabetes, AtherothrombosisIshwarlal Jialal; Fiscal Year: 2010..CRP augments oxidative stress and inflammation in the diabetic milieu will eventually lead to therapies targeted at reducing inflammation and oxidative stress in diabetes and resulting in a decrease in vasculopathies ..
- NUTRITION ACADEMIC AWARDRobert Knopp; Fiscal Year: 2002..It is time to begin aggressive, substantive nutrition educational programs in cardiovascular disease prevention. ..
- REGULATION OF HEPATIC P450S BY ANTICHOLESTEROL DRUGSTHOMAS KOCAREK; Fiscal Year: 2003..These studies will provide information with practical implications for the development of improved anti-cholesterol drugs, and will illuminate mechanisms whereby a cell recognizes, responds to, and metabolizes foreign chemicals. ..
- MOLECULAR & CLINICAL EVALUATION OF LOW HDL SYNDROMESMichael Miller; Fiscal Year: 2003..Further understanding of the molecular basis of isolated low HDL-C and its potential clinical sequelae (e.g., CAD), may therefore aid in the development of therapeutic strategies to effectively treat this disorder. ..
- EFFECT OF HIGH DOSE VITAMIN E ON CAROTID ATHERSCLEROSISIshwarlal Jialal; Fiscal Year: 2001..If this study show that high-dose AT supplementation is beneficial in retarding atherosclerosis this could emerge as an important adjunctive therapy in the management of cardiovascular disease. ..
- NUTRITION ACADEMIC AWARDMichael Miller; Fiscal Year: 2004..Compliance with ATP II and JNC VI recommendations will also be assessed. In addition, medical students' diets and blood lipid levels will be assessed and tracked. ..
- Regulation of Hepatic P450s by Anti-Cholesterol DrugsTHOMAS KOCAREK; Fiscal Year: 2007..These studies will provide essential new information about the pharmacology of a widely-used class of drugs, and important insights into the mechanisms underlying inducible P450 expression. ..
- Obesity, Inflammation and Thrombosis: LOOK AHEADChristie Ballantyne; Fiscal Year: 2009....
- ALPHA AND BETA CELL FUNCTION IN NORMAL AND DIABETIC MANJohn Gerich; Fiscal Year: 2002..Better understanding of the pathogenesis of hypoglycemia unawareness and abnormal glucose counterregulation should make treatment of diabetes safer and improve the chances of achieving optimal glycemic control. ..
- Role of PPARalpha and L-FABP in Acute Renal FailureDidier Portilla; Fiscal Year: 2007....
- HDL and Vascular Injury in Type 2 DiabetesC White; Fiscal Year: 2007....
- AIM HIGH: Niacin Plus Statin to Prevent Vascular EventsBruce Brown; Fiscal Year: 2007..In summary, statins have little effect on HDL-C orTG, and only moderately reduce CV risk. AIM-HIGH is designed to confirm a substantially greater benefit from "complete" lipid therapy using statins plus niacin. ..
- Myeloperoxidase and NO signaling in the vasculatureC White; Fiscal Year: 2004..The HOCI-dependent modification of L-arginine may represent a common pathogenic mechanism underlying endothelial dysfunction in diverse cardiovascular diseases. ..
- Applied Preventive Cardiology ResearchLori Mosca; Fiscal Year: 2007..The research and careers supported by this project are expected to have a positive impact on attainment of the Healthy People 2010 lifestyle and CVD prevention. ..
- ALPHA AND BETA CELL FUNCTION IN NORMAL AND DIABETIC MANJohn Gerich; Fiscal Year: 2007..Further knowledge of the control of renal glucose release could therefore have therapeutic implications for this disorder and in people with liver and kidney disease. ..
- MAC 1/LFA 1/P150 95 AND PMN LEUKOCYTE FUNCTIONChristie Ballantyne; Fiscal Year: 2002..3. Characterize the contribution of each CD11 integrin on the host response to common bacterial and fungal pathogens in vitro and in vivo. ..
- The Effect of Statins on Skeletal Muscle FunctionPaul Thompson; Fiscal Year: 2009....
- PROTEASE INHIBITOR-INDUCED HYPERLIPIDEMIA IN AIDSVirgil Brown; Fiscal Year: 2004..These are specific agents that are effective in reducing triglyceride as well as improving insulin resistance. ..
- Effectiveness of a Family Heart Health InterventionLori Mosca; Fiscal Year: 2007..This study will provide important information about the effectiveness of a novel program to identify persons at risk of CHD and increase attainment of Healthy People 2010 Objectives. ..
- The Effect of Statins on Skeletal Muscle FunctionPaul Thompson; Fiscal Year: 2007....